NCT04633772

Use of Angiotensin-(1-7) in COVID-19

Completed Phase 1, PHASE2 Last updated 9 November 2021

What this trial tests

Phase 1, PHASE2 trial testing Angiotensin-(1-7) in Infection, Coronavirus in 112 participants. Completed in 1 November 2021.

Timeline

5 August 2020

Primary endpoint
1 November 2021

1 November 2021

Quick facts

Lead sponsor	Erasme University Hospital
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	112
Start date	5 August 2020
Primary completion	1 November 2021
Estimated completion	1 November 2021
Sites	2 locations across Brazil

Drugs / interventions tested

• Angiotensin-(1-7)
• Placebo

Conditions studied

• Infection, Coronavirus — all drugs for Infection, Coronavirus →
• Respiratory Failure — all drugs for Respiratory Failure →

Sponsor

Erasme University Hospital

Who can join

Adults 17 to 81, any sex, with Infection, Coronavirus or Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and its supplementation may potentially helpful in this setting.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Cardiac involvement in the long-term implications of COVID-19.
   Satterfield BA, Bhatt DL, Gersh BJ. · · 2022 · cited 101× · PMID 34686843 · DOI 10.1038/s41569-021-00631-3
2. Increased circulating levels of angiotensin-(1-7) in severely ill COVID-19 patients.
   Valle Martins AL, da Silva FA, Bolais-Ramos L, de Oliveira GC, et al · · 2021 · cited 44× · PMID 34350288 · DOI 10.1183/23120541.00114-2021
3. COVID-19 and Hypertension: The What, the Why, and the How.
   Muhamad SA, Ugusman A, Kumar J, Skiba D, et al · · 2021 · cited 43× · PMID 34012410 · DOI 10.3389/fphys.2021.665064
4. The Role of Renin-Angiotensin-Aldosterone System in the Heart and Lung: Focus on COVID-19.
   Mascolo A, Scavone C, Rafaniello C, De Angelis A, et al · · 2021 · cited 34× · PMID 33959029 · DOI 10.3389/fphar.2021.667254
5. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.
   Issa H, Eid AH, Berry B, Takhviji V, et al · · 2021 · cited 28× · PMID 33816521 · DOI 10.3389/fmed.2021.620990
6. Quantifying Renin-Angiotensin-System Alterations in COVID-19.
   Pucci F, Annoni F, Dos Santos RAS, Taccone FS, et al · · 2021 · cited 27× · PMID 34685735 · DOI 10.3390/cells10102755
7. The interacting physiology of COVID-19 and the renin-angiotensin-aldosterone system: Key agents for treatment.
   Lumbers ER, Head R, Smith GR, Delforce SJ, et al · · 2022 · cited 25× · PMID 35106954 · DOI 10.1002/prp2.917
8. SARS-CoV-2 and hypertension.
   Ravichandran B, Grimm D, Krüger M, Kopp S, et al · · 2021 · cited 19× · PMID 34121359 · DOI 10.14814/phy2.14800